3rd Quarter - Report

HEALTHCARE INSTITUTE OF NEW JERSEY for HEALTHCARE INSTITUTE OF NEW JERSEY

Firm
Client
Income
—
Expenses
$160,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

promoting awareness and advocacy of the biopharmaceutical and medical technology industry in New Jersey Eshoo-Barton Pathways to Biosimilars Act HR 1548 Kennedy Pathways to Biosimilars Act Chronic disease prevention and treatment incentives in health care reform America's Affordable Health Choices Act HR.3200 America's Healthy Future Act

LobbyistCovered position, as disclosed
JOHN DUTHIE —
ROBERT D FRANKS Member of Congress 1992-2000
STEVE ISSENMAN Congressional Page1987-1988 Intern 1990
SARAH G KAN Congressional Aid 1999-2002

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3200 (111th), H.R. 1548 (111th)

Medicare/Medicaid MMM

Advocating on behalf of Medicare Part D open access and encouraging open market access to medications

LobbyistCovered position, as disclosed
JOHN DUTHIE —
ROBERT D FRANKS Member of Congress 1992-2000
STEVE ISSENMAN Congressional Page 1987-88 Intern 1990
SARAH G KAN Congressional Aid 1999-2002

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Torts TOR

Medical Device Safety Act of 2009

LobbyistCovered position, as disclosed
JOHN DUTHIE —
SARAH G KAN Congressional Aid 1999-2002

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Affiliated organisations

OrganisationLocation
PARTNERSHIP TO FIGHT CHRONIC DISEASE/ Washington, DC, US
PHRMA Washington, DC, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.